real-time news and commentary for investors
Wednesday, May 29
Pfizer (PFE -2%) says that UPM Pharmaceuticals, a Baltimore-based drug development and contract...
Pfizer (PFE -2%) says that UPM Pharmaceuticals, a Baltimore-based drug development and contract manufacturer, has acquired the 500K square-foot commercial manufacturing facility that PFE currently operates in Bristol, Tenn. The new facility gives UPM the capability to annually produce 3.5B tablets and 680M capsules. As part of the purchase, UPM will continue to manufacture PFE's current portfolio of products within the facility for two years.